# High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study

> **NCT01083342** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 36 (actual)

## Conditions studied

- CNS Lymphoma

## Interventions

- **DRUG:** MTX, MVD, VIA

## Key facts

- **NCT ID:** NCT01083342
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2012-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01083342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01083342, "High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01083342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*